Advertisement: Cambridge Enterprise mid banner
Advertisement: Simpsons Creative
Barr Ellison Solicitors – commercial property
ARM Innovation Hub
Advertisement: China mid banner
Advertisement: Innova Systems
RealVNC mid banner careers
RealVNC mid-banner general
Advertisement: EBCam mid banner
Advertisement: Cambridge Network
Advertisement EY mid banner
Mid banner advertisement: BDO
Advertisement: RSM
Advertisement: Mogrify
28 January, 2019 - 09:39 By Tony Quested

Abcam rabbit punch lands knockout California antibody acquisition

Cambridge life science innovator Abcam saw its UK share price head north after revealing that it had acquired rabbit monoclonal antibodies specialist Calico Biolabs in California for an undisclosed sum.

Calico develops custom high-quality recombinant rabbit monoclonal antibodies for diagnostic and biopharmaceutical companies.

The deal strategically expands Abcam’s leading position in rabbit monoclonal antibodies, bringing a small catalogue of ready-made CAL antibodies™ for immunohistochemistry (IHC) in addition to custom development services. Calico partners with many of the leaders in diagnostics and biopharmaceuticals to create custom products for companion diagnostics.

Calico’s range of ready-made recombinant CAL antibodies™ for critical immuno-oncology targets will be made available at both research and commercial scale, via the Abcam global commercial network.

Financial terms of the transaction have not been disclosed and are expected to have a minimal impact on revenue and earnings for FY2019. 

John Baker, SVP of Product Portfolio and Innovation at Abcam, said: “The acquisition of Calico represents execution of our strategy to provide the best and highest quality products to our diagnostic, biopharmaceutical and research customers.

“By incorporating Calico’s product portfolio and custom services, Abcam expands its offering of rabbit monoclonals for IHC, allowing development of more products for their most important targets, faster.

“We are excited to welcome the Calico team to the Abcam family, furthering Abcam’s mission to provide customers with the highest quality recombinant antibodies for their research.”

Jacinto Villanueva, CEO of Calico, added: “Abcam is a recognised leader for the supply of high-quality validated antibodies, supported by an innovative approach to production and commercialisation, and we are excited to be joining the team. 

“This move will enable us to more fully support the cancer research and associated diagnostics development being carried out by our industry partners.”

Newsletter Subscription

Stay informed of the latest news and features